You have free access to this content

Cancer

Cover image for Cancer

1 May 2006

Volume 106, Issue 9

Pages 1865–2085

  1. Review Article

    1. Top of page
    2. Review Article
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      Why do men choose one treatment over another? : A review of patient decision making for localized prostate cancer (pages 1865–1874)

      Steven B. Zeliadt, Scott D. Ramsey, David F. Penson, Ingrid J. Hall, Donatus U. Ekwueme, Leonard Stroud and Judith W. Lee

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21822

      Few issues are reported in the literature to be consistently important when making treatment decisions for localized prostate cancer. Variations in treatment decisions do not appear to be truly reflective of patient preferences, but rather are more likely to reflect differences in both the content and the methods by which patients receive information.

  2. Original Articles

    1. Top of page
    2. Review Article
    3. Original Articles
    4. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Economic burden associated with breast cancer recurrence : Findings from a retrospective analysis of health system data (pages 1875–1882)

      Lois Lamerato, Suzanne Havstad, Sanjay Gandhi, David Jones and David Nathanson

      Article first published online: 29 MAR 2006 | DOI: 10.1002/cncr.21824

      The economic burden of breast cancer recurrence is poorly understood. For this cohort study, the authors examined the economic burden of breast cancer recurrence by comparing healthcare-related costs for patients with and without recurrence and by comparing charges for different recurrence types.

    2. You have free access to this content
      Breast cancer incidence after the introduction of mammography screening : What should be expected? (pages 1883–1890)

      Anne Louise Svendsen, Anne Helene Olsen, My von Euler-Chelpin and Elsebeth Lynge

      Article first published online: 29 MAR 2006 | DOI: 10.1002/cncr.21823

      A “natural experiment” study was undertaken in Denmark, which has 2 regions with mammography screening programs and 13 regions without such programs. Comparison of regional trends in breast cancer incidence was not found to provide evidence of the overdiagnosis of invasive breast cancer in the 2 screening regions, or, if overdiagnosis was found to occur, it was only of limited magnitude.

    3. Endocrine Disease
      You have free access to this content
      Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression (pages 1891–1900)

      Beatriz S. Stolf, Mariana M. S. Santos, Daniel F. Simao, Juan P. Diaz, Elier B. Cristo, Roberto Hirata Jr., Maria P. Curado, Eduardo J. Neves, Luiz P. Kowalski and Alex F. Carvalho

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21826

      The authors used data from gene expression analysis to search for expression signatures of individual samples of adenomas and follicular carcinomas that could be used as molecular classifiers for the precise classification of malignant and nonmalignant lesions. The results indicated that these classifiers may have value as diagnostic tools in fine-needle aspiration biopsy samples and, ultimately, may help to reduce the numbers of patients who undergo unnecessary thyroidectomy.

    4. You have free access to this content
      Preoperative steroid pulse therapy for invasive thymoma : Clinical experience and mechanism of action (pages 1901–1907)

      Yoshihiro Kobayashi, Yoshitaka Fujii, Motoki Yano, Hidefumi Sasaki, Haruhiro Yukiue, Hiroshi Haneda, Eriko Suzuki, Katsuhiko Endo and Osamu Kawano

      Article first published online: 5 APR 2006 | DOI: 10.1002/cncr.21875

      The purpose of the study was to evaluate the efficacy of intravenous high-dose glucocorticoid (steroid pulse) therapy in patients with previously untreated advanced thymoma. Causes were also sought for a possible underlying mechanism of the effect of steroid on thymoma.

    5. Gastrointestinal Tract
      You have free access to this content
      An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer : The GC4 study (pages 1908–1916)

      Jaffer A. Ajani, J. Randolph Hecht, Linus Ho, Jackie Baker, Marga Oortgiesen, Arnavaz Eduljee and Dov Michaeli

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21814

      The authors evaluated a G17DT vaccination that was given with combined cisplatin and 5-fluorouracil for the treatment gastric adenocarcinoma. The results demonstrated that successful G17DT vaccination was correlated with longer time to disease progression and median survival and that antigastrin antibody response was an independent predictor of overall survival.

    6. Genitourinary Disease
      You have free access to this content
      Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer (pages 1917–1924)

      George Wilding, Patrick Soulie, Donald Trump, Ashis Das-Gupta and Eric Small

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21831

      The results of the current study demonstrated that the combination of gefitinib with docetaxel and estramustine in the treatment of hormone-refractory prostate cancer had an acceptable and predictable tolerability profile. However, it was not clear from these data whether gefitinib provided an additional clinical benefit over docetaxel and estramustine alone.

    7. Gynecologic Oncology
      You have free access to this content
      Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma (pages 1925–1932)

      Daniel G. Rosen, Gong Yang, Michael T. Deavers, Anais Malpica, John J. Kavanagh, Gordon B. Mills and Jinsong Liu

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21767

      Cyclin E, which is a key regulator of the cell cycle at the G1/S transition, is expressed at much greater levels in malignant tumors of the ovary compared with its expression in benign lesions and in normal ovarian surface epithelium. The results from this study indicated that cyclin E overexpression is associated with poor survival in both univariate and multivariate analysis of all factors that influence survival and that cyclin E is an independent prognostic factor in patients with ovarian carcinoma.

    8. You have free access to this content
      Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma (pages 1933–1939)

      Dennis S. Chi, Kristina McCaughty, John P. Diaz, Jae Huh, Sarah Schwabenbauer, Amanda J. Hummer, Ennapadam S. Venkatraman, Carol Aghajanian, Yukio Sonoda, Nadeem R. Abu-Rustum and Richard R. Barakat

      Article first published online: 29 MAR 2006 | DOI: 10.1002/cncr.21845

      In patients with platinum-sensitive, recurrent ovarian cancer who underwent secondary cytoreduction, multivariate analysis identified disease-free interval, number of recurrence sites, and residual disease as significant prognostic factors. These factors should be used as selection criteria for offering secondary cytoreduction.

    9. Head and Neck Disease
      You have free access to this content
      Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas (pages 1940–1949)

      Quynh-Thu Le, Al Taira, Sherie Budenz, Mary Jo Dorie, Don R. Goffinet, Willard E. Fee, Richard Goode, Daniel Bloch, Albert Koong, J. Martin Brown and Harlan A. Pinto

      Article first published online: 10 MAR 2006 | DOI: 10.1002/cncr.21785

      The authors report the results from a randomized trial that evaluated the efficacy and toxicity of adding tirapazamine (TPZ) to chemoradiotherapy in the treatment of patients with resectable head and neck squamous cell carcinomas (HNSCC). The addition of TPZ increased hematologic toxicity but did not improve outcomes in patients with resectable, Stage IV HNSCC using the protocol administered this small randomized study.

    10. You have free access to this content
      Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer (pages 1950–1957)

      Joshua A. Asper, William H. Morrison, David I. Rosenthal, Anesa Ahamad, K. Kian Ang and Adam S. Garden

      Article first published online: 5 APR 2006 | DOI: 10.1002/cncr.21867

      The original staging of 875 oropharynx tumors irradiated over a 23-year period was updated according to the 6th edition of the American Joint Committee on Cancer staging criteria. The distinction between T4a and T4b established by the new criteria was found to be valid with respect to prediction of both local control and overall survival rates.

    11. Hematologic Malignancies
      You have free access to this content
      Complete response in multiple myeloma : Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation (pages 1958–1966)

      Robert A. Kyle, Traci Leong, Shuli Li, Martin M. Oken, Neil E. Kay, Brian Van Ness and Philip R. Greipp

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21804

      Median survival is longer in patients with multiple myeloma achieving a complete response with chemotherapy than in those who obtain a partial response. Molecular complete response is not achieved when polymerase chain reaction is performed.

    12. You have free access to this content
      Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients (pages 1967–1973)

      Maha Boktour, Hend Hanna, Shoaib Ansari, Boulos Bahna, Ray Hachem, Jeffrey Tarrand, Kenneth Rolston, Amar Safdar and Issam Raad

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21846

      In a retrospective study of Stenotrophomonas maltophilia bacteremia in cancer patients with indwelling catheters, it was determined that the catheter is the leading source of the bacteremia. Catheter-related bacteremias tend to be polymicrobial, occurring in noncritically ill nonneutropenic patients. Removal of the catheter may improve outcome in patients with catheter-related S. maltophilia bacteremia.

    13. You have free access to this content
      Thalidomide therapy for myelofibrosis with myeloid metaplasia (pages 1974–1984)

      Deborah A. Thomas, Francis J. Giles, Maher Albitar, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Susan M. O'Brien, Guillermo Garcia-Manero, Michael J. Keating, Sherry Pierce, Jerome Zeldis and Hagop M. Kantarjian

      Article first published online: 31 MAR 2006 | DOI: 10.1002/cncr.21827

      Patients who had myelofibrosis with myeloid metaplasia (MMM) received treatment with dose escalated thalidomide in a Phase II clinical trial. Detailed assessments of angiogenesis (including serum levels and bone marrow microvessel density) were performed. The results indicated that thalidomide warrants further evaluation in patients with MMM, particularly in combination regimens, along with the investigation of newer analogs.

    14. You have free access to this content
      Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis (pages 1985–1989)

      David Dingli, Susan M. Schwager, Ruben A. Mesa, Chin-Yang Li, Gordon W. Dewald and Ayalew Tefferi

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21868

      Postpolycythemic and postthrombocythemic myeloid metaplasia are consensually referred to as secondary myelofibrosis (sMF). Prognostic variables in sMF are not as well defined as they are for de novo myelofibrosis with myeloid metaplasia, which is also known as agnogenic myeloid metaplasia (AMM). Such information is particularly crucial for management decisions in transplant-eligible patients. In the current study, these issues were addressed by a single institutional study of 66 young patients with sMF and the findings were compared with a temporal cohort of age-matched patients with AMM to recognize similarities as well as differences.

    15. Hepatobiliary Disease
      You have free access to this content
      Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion (pages 1990–1997)

      Shuntaro Obi, Haruhiko Yoshida, Risa Toune, Tadao Unuma, Miho Kanda, Shinpei Sato, Ryosuke Tateishi, Takuma Teratani, Shuichiro Shiina and Masao Omata

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21832

      The combination of intraarterial 5-fluorouracil (FU) and systemic interferon-α (IFNα) was effective against hepatocellular carcinoma with portal venous invasion. The combination therapy was safe, and substantially improved survival rates among the complete responders.

    16. Lung Disease
      You have free access to this content
      Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis (pages 1998–2004)

      Chaosu Hu, Eric L. Chang, Samuel J. Hassenbusch III, Pamela K. Allen, Shiao Y. Woo, Anita Mahajan, Ritsuko Komaki and Zhongxing Liao

      Article first published online: 29 MAR 2006 | DOI: 10.1002/cncr.21818

      Aggressive treatment to the lung may be justified for newly diagnosed thoracic Stage I nonsmall cell lung cancer patients with a solitary brain metastasis but not for locally advanced nonsmall cell lung cancer patients with a solitary brain metastasis.

    17. Melanoma
      You have free access to this content
      Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma : Significant toxicity with no clinical efficacy (pages 2005–2011)

      Ken Wyman, Michael B. Atkins, Victor Prieto, Omar Eton, David F. McDermott, Francie Hubbard, Christine Byrnes, Kathleen Sanders and Jeffrey A. Sosman

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21834

      Imatinib at its maximum tolerated dose demonstrated no clinical antitumor activity in patients with advanced melanoma. Treatment demonstrated significant toxicity in these patients requiring dose reductions and removal from treatment in some cases.

    18. You have free access to this content
      Metastatic melanoma to lymph nodes in patients with unknown primary sites (pages 2012–2020)

      Janice N. Cormier, Yan Xing, Lei Feng, Xuelin Huang, Latunya Davidson, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield and Merrick I. Ross

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21835

      Metastatic melanoma in lymph nodes of unknown primary origin (MUP) is not an uncommon clinical scenario: It occurs in approximately 9% of patients who present with lymph node metastases. The overall 5-year and 10-year survival rates for patients with MUP are 55% and 44%, respectively, which are similar to rates for patients with Stage IIIB melanoma.

    19. Neuro-Oncology
      You have free access to this content
      Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis (pages 2021–2027)

      Marc C. Chamberlain, Denice D. Tsao-Wei and Susan Groshen

      Article first published online: 31 MAR 2006 | DOI: 10.1002/cncr.21828

      Intracerebrospinal fluid (CSF) etoposide has activity in patients with neoplastic meningitis similar to that observed with liposomal cytarabine.

    20. Sarcoma
      You have free access to this content
      Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1β (pages 2028–2038)

      Thomas Kalinski, Sabine Krueger, Saadettin Sel, Kerstin Werner, Martin Ropke and Albert Roessner

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21848

      Angiogenic signaling in cartilage tumors is variable. Its regulation by interleukin-1β has implications for medical treatment.

    21. Discipline

      Epidemiology
      You have free access to this content
      Estimates of long-term survival for newly diagnosed cancer patients : A projection approach (pages 2039–2050)

      Angela B. Mariotto, Margaret N. Wesley, Kathleen A. Cronin, Karen A. Johnson and Eric J. Feuer

      Article first published online: 29 MAR 2006 | DOI: 10.1002/cncr.21803

      The authors developed a method for projecting the survival of patients with newly diagnosed cancer and compared it with other predictive methods. The new method, which is a natural extension of prior methods for modeling relative survival, consists of fitting a regression model to survival rates, using the year of diagnosis as a regression parameter, and extrapolating fitted trends not yet reported to obtain survival estimates for patients who are diagnosed in the current calendar year.

    22. Medical Oncology
      You have free access to this content
      Clinical features and correlates of gemcitabine-associated lung injury : Findings from the RADAR project (pages 2051–2057)

      Steven M. Belknap, Timothy M. Kuzel, Paul R. Yarnold, Nicholas Slimack, E. Allison Lyons, Dennis W. Raisch and Charles L. Bennett

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21808

      High rates of gemcitabine-associated severe lung injury were observed when gemcitabine was combined with other therapies known to also cause lung injury. Physicians should have a high index of suspicion for this toxicity and report the relevant clinical findings to the Food and Drug Administration's Adverse Event Reporting System.

    23. You have free access to this content
      The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site : A population-based study (pages 2058–2066)

      Pascal Seve, Michael Sawyer, John Hanson, Christiane Broussolle, Charles Dumontet and John R. Mackey

      Article first published online: 31 MAR 2006 | DOI: 10.1002/cncr.21833

      In this study, the authors provide the first report to their knowledge on how comorbidities and referral bias relate to the administration of chemotherapy and to the prognosis of patients with carcinomas of unknown primary (CUP). By examining their extensive population-based registry and patient charts, the authors investigated the substantial differences in registry-based descriptions of CUP and referral-center descriptions of CUP.

    24. Pediatric Oncology
      You have free access to this content
      Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor (pages 2067–2075)

      Annemieke I. Buizer, Leo M. J. de Sonneville, Marry M. van den Heuvel-Eibrink and Anjo J. P. Veerman

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21820

      Evidence is provided of subtle but significant behavioral and educational problems in survivors of childhood acute lymphoblastic leukemia (ALL), but no dysfunctions in survivors of a Wilms tumor. Careful follow-up of children with ALL treated with chemotherapy only is warranted.

    25. Psychological Oncology
      You have free access to this content
      Effects of weight training on quality of life in recent breast cancer survivors : The Weight Training for Breast Cancer Survivors (WTBS) study (pages 2076–2083)

      Tetsuya Ohira, Kathryn H. Schmitz, Rehana L. Ahmed and Douglas Yee

      Article first published online: 27 MAR 2006 | DOI: 10.1002/cncr.21829

      To examine the effects of weight training on changes in quality of life (QOL) and depressive symptoms, a randomized intervention trial was performed in 86 recent breast cancer survivors. Over 6 months, the physical global and psychosocial global QOL score improved in the treatment group compared with the control group. Increases in upper body strength and lean mass were correlated with improvements in physical global and psychosocial global score, results that show that twice-weekly weight training for recent breast cancer survivors may result in improved QOL, in part, via changes in body composition and strength.

  3. Correspondence

    1. Top of page
    2. Review Article
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 2085)

      Patricia A. Carney

      Article first published online: 24 MAR 2006 | DOI: 10.1002/cncr.21821

SEARCH

SEARCH BY CITATION